Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.560
+0.020 (0.44%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Cingulate Employees
Cingulate had 14 employees as of December 31, 2025. The number of employees increased by 1 or 7.69% compared to the previous year.
Employees
14
Change (1Y)
1
Growth (1Y)
7.69%
Revenue / Employee
n/a
Profits / Employee
-$1,993,523
Market Cap
61.42M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 1 | 7.69% |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -2 | -13.33% |
| Dec 31, 2022 | 15 | -1 | -6.25% |
| Dec 31, 2021 | 16 | 4 | 33.33% |
| Sep 30, 2021 | 13 | 1 | 8.33% |
| Jun 30, 2021 | 13 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 139 |
| Elicio Therapeutics | 33 |
| Cardiff Oncology | 31 |
| Boundless Bio | 28 |
| LeonaBio | 19 |
| ImageneBio | 17 |
| Edesa Biotech | 17 |
| Context Therapeutics | 15 |
CING News
- 19 days ago - Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® - GlobeNewsWire
- 5 weeks ago - Cingulate issues patent by USPTO for CTx-1301 - TheFly
- 5 weeks ago - Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - GlobeNewsWire
- 6 weeks ago - Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - Newsfile Corp
- 6 weeks ago - Roth sees ‘major silver lining’ in Cingulate complete response letter - TheFly
- 6 weeks ago - Cingulate issued complete response letter for CTx-1301 from FDA - TheFly
- 7 weeks ago - US FDA declines to approve Cingulate's ADHD drug - Reuters
- 7 weeks ago - Cingulate Receives Complete Response Letter from FDA for CTx-1301 - GlobeNewsWire